Stratis ST ACL系統(tǒng)是一種新型前十字韌帶重建系統(tǒng)，可以減少手術(shù)時(shí)間和患者的創(chuàng)傷。該系統(tǒng)已經(jīng)獲得美國(guó)食品藥品管理局的許可。

該系統(tǒng)是根據(jù)以及獲得技術(shù)設(shè)計(jì)制造的，包括使用可生物吸收聚合體材料制造的可重復(fù)使用的工具和固定植入體。系統(tǒng)允許外科醫(yī)生使用關(guān)節(jié)內(nèi)窺鏡檢查操作，從而減少了手術(shù)時(shí)間和患者的創(chuàng)傷。該技術(shù)通過(guò)減少了手術(shù)步驟、免除了復(fù)雜費(fèi)時(shí)的測(cè)量而將外科手術(shù)方案簡(jiǎn)化。Stratis植入體提供了組織到骨的通道壓縮以及在股骨關(guān)節(jié)線固定，這是需要外科醫(yī)生鑒別的兩個(gè)關(guān)鍵區(qū)域，而使用當(dāng)前技術(shù)無(wú)法進(jìn)行鑒別。

Stratis系統(tǒng)由美國(guó)Scandius BioMedical公司(Littleton, MA, USA)研制成功，該公司目前關(guān)注重點(diǎn)是關(guān)節(jié)內(nèi)窺鏡檢查操作進(jìn)行軟組織前十字韌帶重建，未來(lái)發(fā)展將涉及關(guān)節(jié)軟骨、半月板修補(bǔ)以及其它運(yùn)動(dòng)相關(guān)性軟組織與關(guān)節(jié)損傷。

Scandius生物醫(yī)學(xué)公司創(chuàng)始人、主席、首席執(zhí)行官M(fèi)ark A. Johanson說(shuō)：“我們相信Stratis將為外科醫(yī)生提供手術(shù)與臨床的效益，我們十分高興將這項(xiàng)革新技術(shù)應(yīng)用于外科醫(yī)生迫切需求改進(jìn)的領(lǐng)域，”
 
Patented ACL Reconstruction System 
 
A new anterior cruciate ligament (ACL) reconstruction system is designed to reduce both surgical time and patient trauma. Called Stratis ST ACL, the system has been cleared by the U.S. Food and Drug Administration (FDA).

The system is based on patented technology comprising reusable instruments and a fixation implant manufactured from both bioabsorbable and polymer materials. By allowing a surgeon to perform the procedure arthroscopically, both surgical time and patient trauma are reduced. The technology simplifies the surgical procedure by reducing the number of steps needed to perform the technique while also eliminating complicated, time-consuming measurements. The Stratis implant provides tissue-to-bone tunnel compression and fixation at the joint line of the femur, two key areas of need that surgeons have identified as unmet with current technology.

Stratis was developed by Scandius BioMedical, Inc. (Littleton, MA, USA), whose current focus is on arthroscopic soft tissue ACL reconstruction, with future developments addressing the areas of articular cartilage, meniscal repair, and other soft-tissue sports-related joint injuries.

“We believe Stratis will provide surgeons both surgical and clinical benefits, and we are excited to bring an innovative technology solution in an area where surgeons have expressed a need for advancement,” said Mark A. Johanson, founder, president, and CEO of Scandius BioMedical.